Pfizer says that it is "reviewing strategic alternatives" for its Capsugel business and that divestiture is an option. Capsugel manufactures capsules, including Vcaps hypromellose capsules for inhalation applications, and the Xcelodose powder dispensing system. 2009 revenue for Capsugel was approximately $740 million. Pfizer expects to make a decision early in 2011. Read the company’s press release.
Pfizer considers divesting Capsugel
published on
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
